Honasa Consumer Limited

Honasa Consumer Limited

Honasa Consumer Limited has informed the Exchange about Investor Presentation, enclosing unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to be made at the Earnings Conference Call.

Honasa Consumer Limited

Honasa Consumer Limited has announced the outcome of its board meeting, where the board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results along with the limited review report issued by the statutory auditors are enclosed with the announcement.

Honasa Consumer Limited

Honasa Consumer Limited has announced a meeting with analysts and investors on August 18, 2026, at the 'Ambit-Daiwa India Access' conference in Singapore. The meeting will be held from 9:00 am to 5:00 pm (SGT) or 6:30 am to 2:30 pm (IST). The schedule is subject to change due to exigencies.

Honasa Consumer Limited

Honasa Consumer Limited has disclosed a judgment by the Cassation Court in Dubai, UAE, which rejects the appeals of both parties and upholds the award of AED 1,707,407.06 to RSM for material and moral damages. The company expects no financial impact due to the reliefs granted by the Arbitral Tribunal.

Honasa Consumer Limited

Honasa Consumer Limited has appointed Nilesh Kotalwar as its Chief Marketing Officer, effective August 6, 2026, to lead the company's integrated marketing function across its portfolio of brands.

Honasa Consumer Limited

Honasa Consumer Limited has informed the Exchange about the schedule of Q1 FY 2027 Earnings Conference Call, to be held on August 13, 2026, at 5:30 pm IST.

Honasa Consumer Limited

Honasa Consumer Limited has provided a quarterly update for Q1 FY2026-27, expecting strong YoY growth in revenue, driven by continuous growth momentum across focus categories, with Mamaearth brand accelerating its growth momentum and delivering high-teens growth YoY.

Honasa Consumer Limited

Honasa Consumer Limited has incorporated a wholly owned subsidiary, Honasa Health Private Limited, as per Regulation 30 of the SEBI Listing Regulations.

Honasa Consumer Limited

Honasa Consumer Limited has received a compliance certificate from KFin Technologies Limited, confirming that no requests for dematerialization of shares were received during the quarter ended June 30, 2026.

Honasa Consumer Limited

Honasa Consumer Limited has received a favorable rectification order in an arbitration proceeding against RSMM General Trading LLC, correcting computational and clerical errors in the initial award, resulting in an increased monetary payout of AED 9,918,514 (approximately INR 25,53,55,217.67) and additional interest penalty if the amount remains unpaid after 30 days.

Honasa Consumer Limited

Honasa Consumer Limited has closed its trading window for insiders from July 1, 2026, until 48 hours after the submission of unaudited Q2 2026 financial results.

Honasa Consumer Limited

Honasa Consumer Limited (HCL) has announced the acquisition of a 58% majority stake in Fluence Pharma, a science-backed nutraceuticals company specializing in patented Cyclical Nutrition Therapy. This strategic move marks HCL's entry into the high-growth nutraceuticals market, particularly focusing on "inside-out" beauty solutions. HCL will establish a new subsidiary, Honasa Health Private Limited, to scale Fluence's B2C nutrition portfolio. Fluence Pharma reported approximately INR 40 Crore revenue with over 20% EBITDA margin in FY26.

Honasa Consumer Limited

Honasa Consumer Limited has approved the acquisition of a majority 58% equity stake in Fluence Pharma Private Limited for approximately ₹135 Crores enterprise value. Fluence Pharma offers condition-specific OTC supplements under brands like "Hair Fact" and "Skin Fact." This strategic move marks Honasa's entry into the rapidly growing nutraceuticals market, which is valued at over ₹16,000 Crores. The company also announced the incorporation of a wholly-owned subsidiary, Honasa Health Private Limited, to manage its B2C nutraceuticals business. The remaining 42% stake in Fluence Pharma will be acquired in two tranches over the next 5-7 years.